Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
Agios Pharmaceuticals ownership update: Lynx1 Capital Management and Weston Nichols report beneficial ownership of 3,013,949 shares of Agios common stock, representing 5.1% of the class. The percentage is calculated using 59,471,609 shares outstanding as of April 24, 2026.
The filing states the shares are held by Lynx1 Master Fund LP with shared voting and dispositive power, and the statement is a joint filing by the Investment Manager and Mr. Nichols.
Agios Pharmaceuticals Inc: Vanguard Capital Management reports beneficial ownership of 3,088,169 shares of Agios common stock, representing 5.27% of the class as of 03/31/2026. Vanguard reports sole dispositive power over the 3,088,169 shares and sole voting power over 455,853 shares. The filing states these holdings reflect positions managed by Vanguard Capital Management LLC and specified affiliates, including shares held by Vanguard funds and managed accounts.
Agios Pharmaceuticals reported first-quarter 2026 product revenue of $20.7 million, up from $8.7 million a year earlier, driven by PYRUKYND® and the late-2025 U.S. launch of AQVESME™ for thalassemia and initial rest-of-world sales.
The company posted a net loss of $99.1 million, or $1.69 per share, as it increased research and development spending to $81.1 million and selling, general and administrative costs to $48.3 million to support its expanding rare-disease portfolio and commercialization.
Agios ended March 31, 2026 with $1.0 billion in cash, cash equivalents and marketable securities, and expects this to fund operations for at least 12 months while advancing mitapivat in thalassemia and sickle cell disease, tebapivat in lower-risk MDS and SCD, AG-181 in PKU, and AG-236 in polycythemia vera.
Agios Pharmaceuticals reported first quarter 2026 results showing rapid growth in its rare disease franchise but continued investment-driven losses. Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million, up from $8.7 million in the first quarter of 2025, supported by a strong U.S. launch of AQVESME in thalassemia with 242 prescriptions written as of March 31, 2026.
Net loss for the quarter was $99.1 million compared to $89.3 million a year earlier, reflecting higher R&D spending of $81.1 million and SG&A expenses of $48.3 million. Cash, cash equivalents and marketable securities totaled $1.0 billion as of March 31, 2026. The company plans to submit a supplemental NDA for mitapivat in sickle cell disease in the second quarter of 2026 and expects Phase 2 tebapivat readouts in myelodysplastic syndromes and sickle cell disease later in 2026.
Agios Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders as a fully virtual webcast on June 18, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 21, 2026, when 59,471,609 common shares were outstanding, may vote.
Items up for vote include electing three Class I directors to terms ending in 2029, an advisory say‑on‑pay vote on executive compensation, approval of an amendment to the 2023 Stock Incentive Plan to increase available shares, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. A majority of outstanding shares, about 29,735,805, is needed for a quorum. The company uses internet “notice and access” and emphasizes ESG initiatives, flexible work culture and extensive governance structures.
Agios Pharmaceuticals Chief Legal Officer James William Burns exercised 8,500 performance share units into 8,500 shares of common stock. The PSUs vested when a specified regulatory milestone was determined to be met on April 2, 2026. On the same date, 3,280 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, Burns directly holds 49,306 shares of Agios common stock.
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Sarah Gheuens exercised performance share units that converted into 8,500 shares of common stock on April 2, 2026 after a specified regulatory milestone was achieved.
Each performance share unit represented a contingent right to receive one share of common stock, and the grant was originally made on March 1, 2024. Following this vesting and exercise, Gheuens sold 2,940 shares of common stock at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, she directly owns 80,277 common shares, which include 311 shares purchased through the company’s employee stock purchase plan.
Agios Pharmaceuticals' Chief Financial Officer Cecilia Jones exercised performance share units and sold shares primarily to cover taxes. She converted 8,500 performance share units into 8,500 shares of common stock after a specified regulatory milestone was determined to have been met on April 2, 2026. On the same date, 3,141 shares were sold at $34.71 per share to satisfy tax withholding obligations under durable automatic sale instructions included in her March 1, 2024 performance share unit agreement, which is structured to be consistent with the Rule 10b5-1(c) affirmative defense. After these transactions, she directly held 54,998 shares of common stock, including 311 shares acquired through the company’s employee stock purchase plan.
Agios Pharmaceuticals Chief Commercial Officer Tsveta Milanova reported a vesting and tax-related sale of shares. On April 2, 2026, 8,500 performance share units were exercised into 8,500 shares of common stock at $0.00 per share, reflecting the vesting of performance-based equity compensation tied to a specified regulatory milestone.
On the same date, 3,262 shares of common stock were sold at $34.71 per share to cover tax withholding obligations, executed under durable automatic sale instructions consistent with Rule 10b5-1(c). After these transactions, Milanova directly owned 46,829 shares of Agios common stock.